Eric Schmidt
2020
In 2020, Eric Schmidt earned a total compensation of $2.5M as Chief Financial Officer at Allogene Therapeutics, a 28% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $220,000 |
|---|---|
| Option Awards | $1,262,643 |
| Salary | $440,000 |
| Stock Awards | $561,176 |
| Total | $2,483,819 |
Schmidt received $1.3M in option awards, accounting for 51% of the total pay in 2020.
Schmidt also received $220K in non-equity incentive plan, $440K in salary and $561.2K in stock awards.
Rankings
In 2020, Eric Schmidt's compensation ranked 4,577th out of 13,090 executives tracked by ExecPay. In other words, Schmidt earned more than 65.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,577 out of 13,090 | 65th |
Division Manufacturing | 1,853 out of 5,621 | 67th |
Major group Chemicals And Allied Products | 721 out of 2,254 | 68th |
Industry group Drugs | 618 out of 1,954 | 68th |
Industry Biological Products, Except Diagnostic Substances | 144 out of 411 | 65th |
Source: SEC filing on April 22, 2021.
Schmidt's colleagues
We found four more compensation records of executives who worked with Eric Schmidt at Allogene Therapeutics in 2020.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019